2024年12月25日 · MIR222 (MicroRNA 222) is an RNA Gene, and is affiliated with the miRNA class. Diseases associated with MIR222 include Tongue Squamous Cell Carcinoma and Glioblastoma. Among its related pathways are Cell differentiation - expanded index and miRNAs involved in DNA damage response.

胃癌患者血浆miR-222 的表达水平显著高于 慢性萎缩性胃炎和健康对照(P < 0.001)，其表达水 平与胃癌的临床分期、淋巴结转移、无瘤生存率和 总体生存率显著相关，提示血浆中的miR-222 可用 于胃癌的早期发现和预后判断 [21] 。Li等[22] 研究发

MicroRNA 222 is a MicroRNA that in humans is encoded by the MIR222 gene, and is a known extracellular RNA (exRNA). [3]

2024年3月14日 · 作者建立了miR-222心脏特异性表达的转基因小鼠并且证实了转基因小鼠miR-222的表达比内源性水平高10倍（TgC-miR-222）。 转基因表达主要在心脏中增加，qPCR显示其骨骼肌中也有适度增加。

2022年5月30日 · MiR-222 was the most abundant miRNA among all upregulated miRNAs (Fig. 1c) and had a higher percentage in TOF than that in controls (Fig. 1d); these results suggested that increased cardiac...

2025年2月8日 · miR-222 confers the resistance of breast cancer cells to adriamycin through suppression of p27(kip1) expression. miR-222 modulates the PPP2R2A/Akt/mTOR axis and thus plays a critical role in regulating proliferation and chemotherapeutic drug resistance.

MiR-222 has been reported to play important roles in a variety of physiological and pathological processes in the heart. Here we reviewed the recent studies about the roles of miR-222 in cardiovascular diseases. MiR-222 may be a potential cardiovascular biomarker and a new therapeutic target in cardiovascular diseases.

2025年3月18日 · Targeting miR-222-engineered extracellular vesicles (TeEVs), tailored with cardiac-ischemia-targeting peptides (CTPs), are developed as ischemic TeEV therapeutics. These TeEVs are encapsulated within mechanical hydrogels to create injectable TeEV-loaded cardiac patches, enabling minimal invasiveness to attenuate IRI.

MiR-221 and miR-222 are two homologous microRNAs, the high expression levels of which have been commonly demonstrated in multiple human cancer types. The miR-221/miR-222 functions have been verified as oncogenes or tumor suppressors.

2024年3月14日 · While miR-222 is necessary for physiological cardiac growth, it inhibits cardiac growth in response to pressure overload and reduces adverse remodelling and cardiac dysfunction. These findings support the model that physiological and pathological hypertrophy are fundamentally different.